Drug Trial Radar · NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,250
Planned (sponsor's estimate)
Start
Feb 21, 2024
Primary completion
Aug 27, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Conditions
- Diabetes Mellitus, Type 2
Interventions
RetatrutideDrug
Administered SC.
SemaglutideDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hemoglobin A1c (HbA1c) (%)Time frame: Baseline, Week 80
Locations
77 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama - Department of Nutrition Sciences
Birmingham, Alabama
Neighborhood Healthcare Institute of Health
Escondido, California
Long Beach Research Institute
Long Beach, California
Valley Clinical Trials, Inc.
Northridge, California
Rancho Cucamonga Clinical Research
Rancho Cucamonga, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Arrow Clinical Trials
Daytona Beach, Florida
New Age Medical Research Corporation
Miami, Florida
South Broward Research
Miramar, Florida
Clinical Research of Central Florida
Winter Haven, Florida
Herman Clinical Research
Suwanee, Georgia
North Georgia Clinical Research
Woodstock, Georgia
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Rocky Mountain Clinical Research
Idaho Falls, Idaho
Deaconess Clinic - Gateway Health Center
Newburgh, Indiana
IMA Clinical Research Monroe - Armand
Monroe, Louisiana
MedStar Health Research Institute (MedStar Physician Based Research Network)
Hyattsville, Maryland
Brigham and Women's Hospital Diabetes Program
Boston, Massachusetts
NECCR PrimaCare Research
Fall River, Massachusetts
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan
Palm Research Center Tenaya
Las Vegas, Nevada
Palm Research Center Sunset
Las Vegas, Nevada
NYC Research INC
Long Island City, New York
Medication Management
Greensboro, North Carolina
Remington Davis Clinical Research
Columbus, Ohio
Alliance for Multispecialty Research, LLC
Norman, Oklahoma
Central States Research
Tulsa, Oklahoma
The Corvallis Clinic, P.C.
Corvallis, Oregon
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Velocity Clinical Research, Dallas
Dallas, Texas
Valley Institute of Research - Fort Worth
Fort Worth, Texas
Juno Research
Houston, Texas
Southern Endocrinology Associates
Mesquite, Texas
Consano Clinical Research, LLC
Shavano Park, Texas
Texas Valley Clinical Research
Weslaco, Texas
Medrasa Clinical Research
Wylie, Texas
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington
IMA Clinical Research West Virginia
Morgantown, West Virginia
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
Fundación Respirar
Buenos Aires, Argentina
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.